Transfusion-associated graft-versus-host disease
| Transfusion-associated graft-versus-host-disease | |
|---|---|
| Other names | TA-GvHD |
| Specialty | Hematology |
Transfusion-associated graft-versus-host disease (TA-GvHD) is a rare complication of blood transfusion, in which the immunologically competent donor T lymphocytes mount an immune response against the recipient's lymphoid tissue.[1] These donor lymphocytes engraft, recognize recipient cells as foreign and mount an immune response against recipient tissues.[2] Donor lymphocytes are usually identified as foreign and destroyed by the recipient's immune system. However, in situations where the recipient is severely immunocompromised, or when the donor and recipient HLA type is similar (as can occur in directed donations from first-degree relatives), the recipient's immune system is not able to destroy the donor lymphocytes. This can result in transfusion associated graft-versus-host disease. This is in contrast with organ/tissue transplant associated GvHD, where matching HLA reduces the incident of the complication.[3]
Signs and symptoms
The clinical presentation is the same as GvHD occurring in other settings, such as bone marrow transplantation. TA-GvHD can develop two days to six weeks after the transfusion.[4] Typical symptoms include:[4]
- fever
- erythematous maculopapular rash, which can progress to generalised erythroderma
- toxic epidermal necrolysis in extreme cases
- hepatomegaly
- diarrhea
Other symptoms can include cough, abdominal pain, dyspnea and vomiting.[5]
Diagnosis
Laboratory findings include pancytopenia, marrow aplasia, abnormal liver enzymes, and electrolyte imbalance (when diarrhea is present).[citation needed]
TA-GvHD can be suspected from a biopsy of the affected skin or liver,[4] and established by HLA analysis of the circulating lymphocytes. This testing can identify circulating lymphocytes with a different HLA type than the tissue cells of the host.[citation needed]
In 2023, the first case of fetal-induced GvHD was reported in the New England Journal of Medicine.[6]
Prevention
Prevention includes gamma irradiation of the lymphocyte-containing blood components such as red blood cells, platelets and granulocytes. Irradiated blood components should be issued in the following situations:[7]
- Intrauterine transfusions
- Prematurity, low birthweight, or erythroblastosis fetalis in newborns
- Congenital immunodeficiencies
- Certain hematologic malignancies (e.g. Hodgkin lymphoma)
- Patients undergoing hematopoietic stem cell transplantation
- Components that are HLA matched, or directed donations from a family member
- Patients receiving fludarabine therapy
- Patients receiving granulocyte transfusions
Treatment
Treatment is supportive. No available form of therapy has proven effective in treating TA-GvHD and it is fatal in more than 90% of cases.[2]
Epidemiology
The incidence of TA-GvHD in immunocompromised patients receiving blood transfusions is estimated to be 0.1–1.0%, and mortality around 80–90%. Mortality is higher in TA-GvHD than in GvHD associated with
The most common
References
- ^ "Complications of Transfusion: Transfusion Medicine: Merck Manual Professional". Retrieved 2009-02-09.
- ^ PMID 27113000.
- PMID 30855823. Retrieved 2023-02-02.
- ^ a b c "National Healthcare Safety Network (NHSN)". www.cdc.gov. 2017-12-29. Retrieved 2018-09-18.
- PMID 21886390.
- ^ A Case of Fetal-Induced Graft-versus-Host Disease
- OCLC 881812415.
Further reading
- Anwar M, Bhatti FA (2003). "Transfusion associated graft versus host disease". Journal of Ayub Medical College, Abbottabad. 15 (3): 56–58. PMID 14727344.
- Gupta A, Bansal D, Dass R, Das A (December 2004). "Transfusion associated graft versus host disease" (PDF). Indian Pediatrics. 41 (12): 1260–1264. PMID 15623910.
- Triulzi DJ (September 1992). "Transfusion associated graft vs. host disease and irradiated blood components". Archived from the original on 2006-07-22.
- Kardon E (8 July 2022). "Transfusion Reactions". EMedicine.